Sanofi 경영진

경영진 기준 점검 2/4

현재 CEO에 대한 정보가 충분하지 않습니다.

핵심 정보

Olivier Charmeil

최고경영자

n/a

총 보수

CEO 급여 비율	n/a
CEO 재임 기간	less than a year
CEO 지분 보유율	n/a
경영진 평균 재임 기간	4.1yrs
이사회 평균 재임 기간	4.9yrs

최근 경영진 업데이트

Recent updates

CEO

Olivier Charmeil (62 yo)

less than a year

재임 기간

Mr. Olivier Charmeil serves as an Executive Vice President of General Medicines at Sanofi and has been its Interim Chief Executive Officer since February 17, 2026 and served as its Head of General Medicine...

리더십 팀

이름	직위	재임 기간	보수	지분
Olivier Charmeil	Interim CEO & Executive VP of General Medicines	less than a year	데이터 없음	데이터 없음
François-Xavier Roger	Executive VP & CFO	1.9yrs	데이터 없음	데이터 없음
Madeleine Roach	Executive VP & Head of Business Operations	2.4yrs	데이터 없음	데이터 없음
Thomas Larsen	Head of Investor Relations & General Medicines	2.2yrs	데이터 없음	데이터 없음
Roy Papatheodorou	Executive VP & General Counsel	4.1yrs	데이터 없음	데이터 없음
Pierre Chancel	Senior Vice President of Global Diabetes and Senior Vice President of Global Marketing	21.6yrs	데이터 없음	데이터 없음
Natalie Bickford	Executive VP & Chief People Officer	5.6yrs	데이터 없음	데이터 없음
Fabrizio Gaudi	Head of Austrian	7.2yrs	데이터 없음	데이터 없음
Erik Wallström	Head of Therapeutic Area - Neurology Development	no data	데이터 없음	데이터 없음
Thomas Triomphe	Executive Vice President of Vaccines	8.2yrs	데이터 없음	데이터 없음
Karin Knobe	TA Head of Rare Diseases & Rare Blood Disorders Development	no data	데이터 없음	데이터 없음
Pablo Sardi	TA Head of Rare & Neurologic Diseases Research	no data	데이터 없음	데이터 없음

4.1yrs

평균 재임 기간

53yo

평균 나이

경험이 풍부한 관리: SNYN.F의 경영진은 경험이 있음으로 간주됩니다(평균 재임 4.1 년).

이사회 구성원

이름	직위	재임 기간	보수	지분
Jean-François Dehecq	Honorary Chairman	15.8yrs	€4.71m	데이터 없음
Serge Weinberg	Honorary Chairman	2.8yrs	€324.96k	데이터 없음
Patrick Kron	Independent Director	11.8yrs	€233.50k	0.000080% $ 85.7k
Lise Kingo	Independent Director	5.9yrs	€162.00k	0.000080% $ 85.7k
Frederic Oudea	Independent Chairman	2.8yrs	€884.84k	0.000080% $ 85.7k
Rachel Duan	Independent Director	5.9yrs	€151.00k	0.000080% $ 85.7k
Carole Ferrand	Independent Director	3.8yrs	€208.75k	0.000080% $ 85.7k
Barbara Lavernos	Director	4.9yrs	€162.00k	0.000080% $ 85.7k
Clotilde Delbos	Independent Director	1.9yrs	€197.75k	0.000080% $ 85.7k
Emile Voest	Independent Director	3.8yrs	€186.75k	0.000080% $ 85.7k
Christophe Babule	Director	7.1yrs	€156.50k	0.000080% $ 85.7k
Wolfgang Laux	Employee Representative Director	4.9yrs	€129.00k	데이터 없음

4.9yrs

평균 재임 기간

61yo

평균 나이

경험이 풍부한 이사회: SNYN.F의 이사회는 경험이 있음으로 간주됩니다(평균 재임 4.9 년).

기업 분석 및 재무 데이터 상태

데이터	최종 업데이트 (UTC 시간)
기업 분석	2026/03/08 07:27
종가	2026/03/06 00:00
수익	2025/12/31
연간 수익	2025/12/31

데이터 소스

당사의 기업 분석에 사용되는 데이터는 S&P Global Market Intelligence LLC에서 제공됩니다. 아래 데이터는 이 보고서를 생성하기 위해 분석 모델에서 사용됩니다. 데이터는 정규화되므로 소스가 제공된 후 지연이 발생할 수 있습니다.

패키지	데이터	기간	미국 소스 예시 ^*
기업 재무제표	10년	손익계산서 현금흐름표 대차대조표	SEC 양식 10-K SEC 양식 10-Q
분석가 컨센서스 추정치	+3년	재무 예측 분석가 목표주가	분석가 리서치 보고서 Blue Matrix
시장 가격	30년	주가 배당, 분할 및 기타 조치	ICE 시장 데이터 SEC 양식 S-1
지분 구조	10년	주요 주주 내부자 거래	SEC 양식 4 SEC 양식 13D
경영진	10년	리더십 팀 이사회	SEC 양식 10-K SEC 양식 DEF 14A
주요 개발	10년	회사 공시	SEC 양식 8-K

^* 미국 증권에 대한 예시이며, 비(非)미국 증권에는 해당 국가의 규제 서식 및 자료원을 사용합니다.

별도로 명시되지 않는 한 모든 재무 데이터는 연간 기간을 기준으로 하지만 분기별로 업데이트됩니다. 이를 TTM(최근 12개월) 또는 LTM(지난 12개월) 데이터라고 합니다. 자세히 알아보기.

분석 모델 및 스노우플레이크

이 보고서 생성에 사용된 분석 모델의 세부 정보는 저희 Github 페이지에서 확인하실 수 있으며, 보고서 사용 방법에 대한 가이드와 Youtube 튜토리얼도 제공합니다.

Simply Wall St 분석 모델을 설계하고 구축한 세계적 수준의 팀에 대해 알아보세요.

산업 및 섹터 지표

산업 및 섹터 지표는 Simply Wall St가 6시간마다 계산하며, 프로세스에 대한 자세한 내용은 Github에서 확인할 수 있습니다.

분석가 소스

Sanofi는 50명의 분석가가 다루고 있습니다. 이 중 17명의 분석가가 우리 보고서에 입력 데이터로 사용되는 매출 또는 수익 추정치를 제출했습니다. 분석가의 제출 자료는 하루 종일 업데이트됩니다.

분석가	기관
John Eade	Argus Research Company
Odile Rundquist	Baader Helvea Equity Research
null null	Banco de Sabadell. S.A.

Sanofi 경영진

경영진 기준 점검 2/4

핵심 정보

최근 경영진 업데이트

Sanofi Announces Resignation of Patrick Kron as Independent Director and Chairman of the Nomination, Governance and Csr Committee

Sanofi Announces Executive Changes

Sanofi Announces Chief Executive Officer Changes

Sanofi Appoints Clotilde Delbos as Chairwoman of the Compensation Committee

Sanofi, Annual General Meeting, Apr 30, 2025

Sanofi Announces Board Changes

Recent updates

Sanofi Announces Resignation of Patrick Kron as Independent Director and Chairman of the Nomination, Governance and Csr Committee

Regeneron Pharmaceuticals, Inc. and Sanofi Announce Positive CHMP Opinion for Dupixent in Treating Chronic Spontaneous Urticaria in Children Aged 2 to 11 Years

Regeneron Pharmaceuticals, Inc. and Sanofi Announces Dupixent (Dupilumab) Approved in the U.S. as the First and Only Medicine for Allergic Fungal Rhinosinusitis (Afrs)

Sanofi's Rilzabrutinib Designates Breakthrough Therapy in the Us and Orphan Drug in Japan for the Treatment of Cold Autoimmune Hemolytic Anemia

Sanofi Announces Executive Changes

Sanofi Announces Chief Executive Officer Changes

Sanofi (ENXTPA:SAN) completed the acquisition of Dynavax Technologies Corporation (NasdaqGS:DVAX).

Sanofi's Venglustat Met All Primary Endpoints in A Phase 3 Study of Type 3 Gaucher Disease

Sanofi’s Rezurock Recommends for EU Approval by the CHMP to Treat Chronic Graft-vs-Host Disease

Sanofi Provides Earnings Guidance for the Year 2026

Sanofi Proposes Dividend for 2025

Sanofi's Amlitelimab Confirms its Potential in Atopic Dermatitis

Sanofi Announces Approval of Myqorzo and Redemplo in China

Sanofi's Tzield Accepts for Priority Review in the Us for Young Children with Stage 2 Type 1 Diabetes

Sanofi (ENXTPA:SAN) agreed to acquire Dynavax Technologies Corporation (NasdaqGS:DVAX) for $1.9 billion.

Sanofi Provides Update on Tolebrutinib in Primary Progressive Multiple Sclerosis

Sanofi's Qfitlia and Cablivi Approves in China, Expanding Care for Rare Diseases

Sanofi (ENXTPA:SAN) completed the acquisition of Vicebio Limited from Medicxi Ventures (UK) LLP, TCG Crossover Management, LLC, venBio LLC, Goldman Sachs Asset Management International, UniQuest Pty Limited and Avoro Capital Advisors LLC.

Regeneron Pharmaceuticals, Inc. and Sanofi Announce European Commission Approves Dupixent (Dupilumab) for the Treatment of Moderate-To-Severe Chronic Spontaneous Urticaria (CSU)

Sanofi's Teizeild Recommends for EU Approval by the CHMP for Patients with Stage 2 Type 1 Diabetes

Sanofi Announces Positive Results from the pivotal LIBERTY- AFRS-AIMS Phase 3 Study

Sanofi Announces New Data from the Alphamedix-02 Phase 2 Study Evaluating Alphamedix

Sanofi’s efdoralprin alfa met all primary and key secondary endpoints in alpha-1 antitrypsin deficiency emphysema phase 2 study

Sanofi's Tzield Accepts for Expanded Review in the US for Stage 3 Type 1 Diabetes Through FDA Commission's National Priority Voucher Pilot Program

Sanofi's High-Dose Influenza Vaccine Demonstrates Superior Protection for Older Adults Against Hospitalization vs Standard-Dose

Sanofi Provides Update on Regulatory Review in the EU for Rezurock to Treat Chronic Graft-Vs-Host Disease

Sanofi's Wayrilz Recommends for Eu Approval by the CHMP to Treat Immune Thrombocytopenia

Sanofi Announces Positive Results from the ALPHAMEDIX-02 Phase 2 Study

Sanofi to Report Q3, 2026 Results on Oct 30, 2026

Sanofi Expands Patient Affordable Program by Offering Access to All Its Insulins for $35 Per Month in the US

Sanofi Announces its SAR446268 Receives US Fast Track Designation for Treatment of Non-Congenital Myotonic Dystrophy Type 1

Thermo Fisher Scientific Inc. (NYSE:TMO) completed the acquisition of Steriles Manufacturing Site in Ridgefield, New Jersey of Sanofi (ENXTPA:SAN).

Sanofi Announces the Us Food and Drug Administration Approves Wayrilz (Rilzabrutinib) in US as First BTK Inhibitor for Immune Thrombocytopenia

Sanofi Confirms Earnings Guidance for the Year 2025

Sanofi's Sarclisa Approves in the EU for the Treatment of Transplant-Efficient Newly Diagnosed Multiple Myeloma

Sanofi Announces BEYFORTUS Reduced Hospital and Doctor Visits for RSV Disease in Babies by 87%

Sanofi (ENXTPA:SAN) entered into an agreement to acquire Vicebio Limited from Medicxi Ventures (UK) LLP, TCG Crossover Management, LLC, venBio LLC, Goldman Sachs Asset Management International, UniQuest Pty Limited and Avoro Capital Advisors LLC for $1.6 billion.

Sanofi (ENXTPA:SAN) completed the acquisition of Blueprint Medicines Corporation (NasdaqGS:BPMC) from Sixth Street Partners, LLC.

Sanofi's Sar446597 Earns Fast Track Designation in the US for Geographic Atrophy Due Toage-Related Macular Debutation

Sanofi Announces Riliprubart Granted Orphan Drug Designation in Japan for Chronic Inflammative Demyelinating Polyneuropathy

Regeneron Pharmaceuticals, Inc. Announces U.S. Food and Drug Administration Approves Dupixent (Dupilumab) for the Treatment of Adult Patients with Bullous Pemphigoid

Sanofi Accelerates Global Shipping of Beyfortus to Prepare Healthcare Providers Months Ahead of 2025-2026 RSV Season

American Society of Clinical Oncology Announces New Sarclisa Data Support Subcutaneous Administration with On-Body Injector

Sanofi (ENXTPA:SAN) agreed to acquire Blueprint Medicines Corporation (NasdaqGS:BPMC) from Sixth Street Partners, LLC for $8.72 billion.

Regeneron Pharmaceuticals, Inc. and Sanofi Announces Phase 3 Trial, AERIFY-1, Evaluating the Investigational Use of itepekimab in Adults

Sanofi (ENXTPA:SAN) entered into a definitive merger agreement to acquire Vigil Neuroscience, Inc. (NasdaqGS:VIGL) for approximately $380 million.

Sanofi Appoints Clotilde Delbos as Chairwoman of the Compensation Committee

Clayton, Dubilier & Rice Fund XII a fund managed by Clayton, Dubilier & Rice, LLC acquired 50% stake in Opella Healthcare Group SAS from Sanofi (ENXTPA:SAN) for around €10 billion.

Sanofi's Respiratory Pipeline Advances with New Data in Asthma and Plans for New Clinical Studies in COPD

Sanofi Announces Tolebrutinib Phase 3 Data Published in NEJM Demonstrate Benefit on disability Progressive Forms

Regeneron Pharmaceuticals, Inc. and Sanofi Announce Ministry of Health, Labour and Welfare in Japan Grants Marketing and Manufacturing Authorization for Dupixent (Dupilumab)

Sanofi Announces Tolebrutinib Regulatory Submission Accepted for Priority Review in the US for Patients with Multiple Sclerosis

Sanofi Adopts FDA-Selected Flu Strains to Ensure Readiness for the 2025-26 Flu Season

Sanofi, Annual General Meeting, Apr 30, 2025

Regeneron Pharmaceuticals, Inc. and Sanofi Announces Dupixent Late-Breaking Positive Pivotal Data in Bullous Pemphigoid Presented At Aad

Sanofi Announces New Duvakitug Data Reinforce Best-In-Class Potential in Ulcerative Colitis and Crohn's Disease

Sanofi Announces Sarclisa Approval in Japan for Patients with Newly Diagnated Multiple Myeloma

Dupixent® (dupilumab) sBLA Accepted for FDA Priority Review for the Targeted Treatment of Bullous Pemphigoid (BP)

Sanofi Announces Update on E.Mbrace Phase 3 Clinical Study

Sanofi Reports Consolidated Impairment of Intangible Assets for the Fourth Quarter Ended December 31, 2024

Sanofi Announces Sarclisa Approval in the EU as the First Anti-CD38 Therapy in Combination with Standard-Of-Care VRd to Treat Transplant-ineligible Newly Diagnated Multiple Myeloma

Sanofi Announces Sarclisa Obtains First Approval in China for the Treatment of Adult Patients with Relapsed or Refractory Multiple Myeloma

Sanofi Announces Board Changes

Sanofi Announces Two Combination Vaccine Candidates for Prevention of Influenza and COVID-19 Granted Fast Track Designation in the US

Frantz Law Group Files Oceanside Unified School District Lawsuit Against Eli Lily, Novo Nordisk, Sanofi, Express Scripts, CVS Caremark, and Optum RX for Insulin Pricing Scheme

Regeneron Pharmaceuticals, Inc. and Sanofi Announces U.S. Food and Drug Administration Accepts for Review the Resubmission of the Supplemental Biologics License Application for Dupixent®?

Regeneron Pharmaceuticals, Inc. and Sanofi Receive European Union Approval For Dupixent In Young Children With Eosinophilic Esophagitis

Sanofi Announces Beyfortus (Nirsevimab) to Be Broadly Available for Babies Born in Ontario, Quebec, Nunavut, Northwest Territories, and the Yukon This Fall

Sanofi Reportedly in Talks with French Government over Opella Sale